Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other Non-Current Liabilities (2016 - 2017)

Cytosorbents' Other Non-Current Liabilities history spans 4 years, with the latest figure at $1.0 million for Q2 2017.

  • Quarterly results put Other Non-Current Liabilities at $1.0 million for Q2 2017, down 42.13% from a year ago — trailing twelve months through Jun 2017 was $1.0 million (down 42.13% YoY), and the annual figure for FY2016 was $1.8 million, up 10.72%.
  • Other Non-Current Liabilities for Q2 2017 was $1.0 million at Cytosorbents, down from $1.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.0 million in Q4 2014 to a low of $1.0 million in Q2 2017.
  • The 4-year median for Other Non-Current Liabilities is $1.7 million (2016), against an average of $1.9 million.
  • The sharpest move saw Other Non-Current Liabilities plummeted 45.12% in 2015, then grew 10.72% in 2016.
  • Year by year, Other Non-Current Liabilities stood at $3.0 million in 2014, then plummeted by 45.12% to $1.6 million in 2015, then grew by 10.72% to $1.8 million in 2016, then plummeted by 42.23% to $1.0 million in 2017.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.0 million, $1.7 million, and $1.8 million for Q2 2017, Q1 2017, and Q4 2016 respectively.